Alnylam Pharmaceuticals Inc. said its board granted CEO Yvonne Greenstreet a special performance-based equity award effective March 2, 2026 under the company’s 2018 stock incentive plan. The award targets 55,373 performance share units, valued at $18.0 million based on the March 2 closing price of $325.07, and can pay out from 50% to 200% depending on the highest 30-day average stock price in the six months before Dec. 31, 2029. Shares vest at 27,687 if the price reaches $500, 55,373 at $600, 83,060 at $700, and 110,746 at $800, with linear interpolation between thresholds and forfeiture if $500 is not achieved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-014728), on March 04, 2026, and is solely responsible for the information contained therein.